Results 151 to 160 of about 384,863 (297)

How the HTAR will contribute to a value‐based decision‐making for medicinal products across the EU

British Journal of Clinical Pharmacology, EarlyView.
The European Union Health Technology Regulation 2021/2282 (HTAR) introduces joint assessment of health technologies (including medicinal products and medical devices) across EU Member States. It was signed into law in 2021 and came into full force in January 2025.
Roisin Adams, Michal Stanak
wiley   +1 more source

Use of certainty-based marking in a second-year medical student cohort: a pilot study

, 2012
Niikee Schoendorfer, David EmmettCentre for Medical Education, Research and Scholarship, School of Medicine, The University of Queensland, AustraliaBackground: Assessments which consider both competence and confidence attempt to provide insight into ...
Schoendorfer N, Emmett D
core  

Moxibustion combinations for diabetic peripheral neuropathy: a network meta-analysis of 40 randomised trials. [PDF]

Front Endocrinol (Lausanne)
Du D, Wang S, Chen X, Wang J, Zhang X, Gao Y.   +5 more
europepmc   +1 more source

Beyond the label: Rethinking off‐label drug use in paediatrics. Towards a scientifically grounded and safer future for paediatric pharmacotherapy

British Journal of Clinical Pharmacology, EarlyView.
Abstract Despite regulatory progress being made in the past two decades, off‐label drug use in paediatrics remains pervasive, with prevalence estimated between 3% and 97% of prescriptions across different clinical settings. Off‐label use—defined as prescribing outside the conditions described in the Summary of Product Characteristics (SmPC)—is often ...
Tjitske M. van der Zanden, Miriam G. Mooij, Matthijs de Hoog, Saskia N. de Wildt   +3 more
wiley   +1 more source

From anthelmintic to neuro‐oncology: A systematic review of mebendazole repurposing for brain tumour therapy

British Journal of Clinical Pharmacology, EarlyView.
Abstract Aim Mebendazole (MBZ), a benzimidazole anthelmintic with established clinical use, has emerged as a repurposing candidate for primary brain tumours due to its multimodal anticancer actions and central nervous system penetrance. This systematic review synthesizes preclinical and clinical evidence evaluating MBZ's efficacy, mechanisms of action ...
Ciara B. Blum, Milli McMenamin, Tessa Khoo, John M. Edwin, Prathibha Jose, Liam A. O’Callaghan   +5 more
wiley   +1 more source

Cost Containment in Climate Change Policy: Alternative Approaches to Mitigating Price Volatility [PDF]

Cap and trade systems are emerging as the front-running policy choice to address climate change concerns in many countries. One of the apparent attractions of this approach is the ability to achieve hard limits on emissions over a control period.
Gilbert E. Metcalf
core  

Do consumers and healthcare professionals report the same adverse event differently? A paired analysis of duplicate vaccine safety reports in Norway

British Journal of Clinical Pharmacology, EarlyView.
Aim This study aimed to compare how Norwegian healthcare professionals (HCPs) and consumers reported the same adverse event (AE) following immunization with vaccines against COVID‐19 during the COVID‐19 pandemic. Specifically, we aimed to compare the extent to which HCPs and consumers reported information relevant for assessing the causal relationship ...
Tommy Emil Dzus, Johaina Sarrage, Hilde Samdal, François Montastruc, Elena Rocca   +4 more
wiley   +1 more source

Efficacy and safety of cannabinoids in the treatment of spasticity in multiple sclerosis: A systematic review of randomized clinical trials

British Journal of Clinical Pharmacology, EarlyView.
Aims This work aimed to evaluate the efficacy and safety of cannabinoids for the treatment of MS‐related spasticity. Methods Systematic searches were conducted in PubMed, EMBASE, and LILACS on 2 December 2025. Randomized controlled trials evaluating natural or synthetic cannabinoids for MS‐related spasticity were included.
Letícia Hamm‐Buiar, Daniela Gorski, Marcela Harumi Kagueiama, Astrid Wiens   +3 more
wiley   +1 more source

Current practice and guideline adherence in renal dose adjustment for patients with chronic kidney disease: A systematic review and meta‐analysis

British Journal of Clinical Pharmacology, EarlyView.
Aims To quantify prescribing adherence to renal dosing recommendations in adults with chronic kidney disease (CKD; Stage 3 and above) and to evaluate the clinical consequences of non‐adherence. Methods This systematic review and meta‐analysis was conducted in accordance with PRISMA 2020 guidelines and registered in PROSPERO (CRD42025620883).
Hager ElGeed, Ahmed Tehemar, Mohamed Gasimelseed, Ahmed Gharaibeh, Muhammad Abdul Hadi, Kazeem Yusuff, Amani Zidan, Ahmed Awaisu   +7 more
wiley   +1 more source

American Society of Hematology 2026 guidelines for the diagnosis and management of severe and very severe acquired aplastic anemia. [PDF]

Blood Adv
Scheinberg P, O'Neal DA, Basquiera AL, Byrne MT, Calado R, Desai R, DeZern AE, Dufour C, Groarke EM, Han H, Hosokawa K, Kansal R, Kulasekararaj A, Mossad SB, Muus P, Patel B, Risitano AM, Schrezenmeier H, Sharma A, Shimamura A, Shimano KA, Tortosa F, Avila C, Ragusa M, Izcovich A, Neumann I.   +25 more
europepmc   +1 more source